Form 4: Pharma-Bio Serv Director Acquires Stock Options

Director Irving L Wiesen of Pharma-Bio Serv, Inc. acquired 20,000 stock options on January 10, 2025.

Summary

• Irving L Wiesen, a director at Pharma-Bio Serv, Inc., has reported the acquisition of 20,000 stock options.
• These options were granted on January 10, 2025, at an exercise price of $0.49 per share.
• The options vest in two equal installments, on July 10, 2025, and July 10, 2026.
• The options expire on January 10, 2030.

Sentiment

Score: 5

Explanation: The document is a routine disclosure of a stock option grant, which is neither positive nor negative in itself. It is a neutral event.

Industry Context

This is a standard SEC Form 4 filing, which is common for company directors and officers who have transactions in the company's securities. It is a routine disclosure and does not indicate any specific industry trend.

Comparison to Industry Standards

• Stock option grants to directors are a common practice across publicly traded companies as part of their compensation packages.
• The vesting schedule of two equal installments is also a typical arrangement.
• The exercise price of $0.49 is specific to Pharma-Bio Serv and would need to be compared to other companies in the same sector to determine if it is standard.

Stakeholder Impact

• The stock option grant may have a minor positive impact on shareholder sentiment as it aligns the director's interests with the company's performance.

Key Dates

Keywords

stock options, director, insider trading, equity, Pharma-Bio Serv, PBSV